Lower Level of Low Density Lipoprotein Cholesterol is Associated with a Higher Increase in the Fractional Flow Reserve in Patients with Fixed-dose Rosuvastatin

Overview

Journal J Atheroscler Thromb

Date 2017 Aug 22

PMID 28824048

Citations 4

Authors

Takehiro Hashikata

Taiki Tojo

Yusuke Muramatsu

Toshimitsu Sato

Ryota Kakizaki

Teruyoshi Nemoto

Kazuhiro Fujiyoshi

Sayaka Namba

Lisa Kitasato

Takuya Hashimoto

Ryo Kameda

Takao Shimohama

Minako Yamaoka-Tojo

Junya Ako

Affiliations

Soon will be listed here.

Abstract

Aim: Fractional flow reserve (FFR) reflects on the diffuse atherosclerosis per coronary artery. It is unknown whether the statin therapy affects long term FFR after stenting. The aim of this study was to evaluate the long term FFR after stent implantation in patients who are intaking fixed-dose rosuvastatin.

Methods: A total of 22 patients with stable angina pectoris were enrolled. The values of FFR were measured before, immediately after, and 18 months after (follow-up day) the implantation of everolimus eluting stent (EES; Promus Element or Promus Element Plus). A fixed dose of rosuvastatin at 5 mg/day was administrated to all patients.

Results: Of the 22 patients, 2 were excluded because of adverse effect of rosuvastatin and in-stent total occlusion after EES implantation. Overall, the values of FFR immediately after and 18 months after EES implantation did not show significant change (from 0.90±0.05 to 0.88±0.06, p=0.16). However, there was a significant negative correlation between low density lipoprotein (LDL) cholesterol level at follow-up day and changes in the value of FFR (p=0.01, r =－0.74). There was an increase in the FFR value after stenting in 8 out of 9 patients with LDL cholesterol level below 75 mg/dl (area under the curve 0.92, p=0.0005).

Conclusions: LDL cholesterol level was associated with the change in the FFR value in patients following stent implantation. Lower LDL cholesterol tended to improve in the long-term FFR, underscoring the importance of lowering LDL cholesterol to prevent the progression of coronary atherosclerosis.

Citing Articles

Analysis of Metabolic Risk Factors for Microcirculation Disorders Post-Percutaneous Coronary Intervention and Predictive Model Construction: A Study on Patients with Unstable Angina.

Li K, Liu S, Wang J, Liu Z, Qi C Rev Cardiovasc Med. 2025; 26(1):25739.

PMID: 39867198 PMC: 11759962. DOI: 10.31083/RCM25739.

Optimal lipid-lowering therapy in patients who were functionally deferred percutaneous coronary intervention.

Abe T, Shimazaki K, Moriyama T, Murohashi A, Iwanami Y, Sasaki A Sci Rep. 2023; 13(1):10880.

PMID: 37407607 PMC: 10322823. DOI: 10.1038/s41598-023-37988-z.

Influence of intensive lipid-lowering on CT derived fractional flow reserve in patients with stable chest pain: Rationale and design of the FLOWPROMOTE study.

Mortensen M, Sand N, Busk M, Jensen J, Grove E, Dey D Clin Cardiol. 2022; 45(10):986-994.

PMID: 36056636 PMC: 9574753. DOI: 10.1002/clc.23895.

Effect of Low-Density Lipoprotein Cholesterol Goal Achievement on Vascular Physiology Evaluated by Quantitative Flow Ratio in Patients Who Underwent Percutaneous Coronary Intervention.

Chen L, Chen Q, Zhong J, Ye Z, Ye M, Yan Y Front Cardiovasc Med. 2021; 8:679599.

PMID: 34222375 PMC: 8249848. DOI: 10.3389/fcvm.2021.679599.

Coronary flow impairment in asymptomatic patients with early stage type-2 diabetes: Detection by FFR.

Mrgan M, Norgaard B, Dey D, Gram J, Olsen M, Gram J Diab Vasc Dis Res. 2020; 17(9):1479164120958422.

PMID: 32985257 PMC: 7919222. DOI: 10.1177/1479164120958422.

References

Wakabayashi K, Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S . Efficacy of Statin Therapy in Inducing Coronary Plaque Regression in Patients with Low Baseline Cholesterol Levels. J Atheroscler Thromb. 2016; 23(9):1055-66. PMC: 5090812. DOI: 10.5551/jat.34660. View

Jin X, Tahk S, Yang H, Lim H, Yoon M, Choi S . The relationship between intravascular ultrasound-derived percent total atheroma volume and fractional flow reserve in the intermediate stenosis of proximal or middle left anterior descending coronary artery. Int J Cardiol. 2015; 185:56-61. DOI: 10.1016/j.ijcard.2015.03.048. View

Stone G, Teirstein P, Meredith I, Farah B, Dubois C, Feldman R . A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de.... J Am Coll Cardiol. 2011; 57(16):1700-8. DOI: 10.1016/j.jacc.2011.02.016. View

Tokuyama T, Sakuma T, Motoda C, Kawase T, Takeda R, Mito S . Intravenous administration of adenosine triphosphate disodium during primary percutaneous coronary intervention attenuates the transient rapid improvement of myocardial wall motion, not myocardial stunning, shortly after recanalization in acute.... J Cardiol. 2009; 54(2):289-96. DOI: 10.1016/j.jjcc.2009.06.002. View

Ng M, Yeung A, Fearon W . Invasive assessment of the coronary microcirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve. Circulation. 2006; 113(17):2054-61. DOI: 10.1161/CIRCULATIONAHA.105.603522. View

Fearon W, Balsam L, Farouque H, Caffarelli A, Robbins R, Fitzgerald P . Novel index for invasively assessing the coronary microcirculation. Circulation. 2003; 107(25):3129-32. DOI: 10.1161/01.CIR.0000080700.98607.D1. View

Yoshino S, Cassar A, Matsuo Y, Herrmann J, Gulati R, Prasad A . Fractional flow reserve with dobutamine challenge and coronary microvascular endothelial dysfunction in symptomatic myocardial bridging. Circ J. 2014; 78(3):685-92. DOI: 10.1253/circj.cj-13-0846. View

Colhoun H, Betteridge D, Durrington P, Hitman G, Neil H, Livingstone S . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435):685-96. DOI: 10.1016/S0140-6736(04)16895-5. View

Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L . Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016; 374(21):2021-31. DOI: 10.1056/NEJMoa1600176. View

10.

Ito T, Tani T, Fujita H, Ohte N . Relationship between fractional flow reserve and residual plaque volume and clinical outcomes after optimal drug-eluting stent implantation: insight from intravascular ultrasound volumetric analysis. Int J Cardiol. 2014; 176(2):399-404. DOI: 10.1016/j.ijcard.2014.07.115. View

11.

Hou J, Xing L, Jia H, Vergallo R, Soeda T, Minami Y . Comparison of Intensive Versus Moderate Lipid-Lowering Therapy on Fibrous Cap and Atheroma Volume of Coronary Lipid-Rich Plaque Using Serial Optical Coherence Tomography and Intravascular Ultrasound Imaging. Am J Cardiol. 2016; 117(5):800-6. DOI: 10.1016/j.amjcard.2015.11.062. View

12.

de Bruyne B, Hersbach F, Pijls N, Bartunek J, Bech J, Heyndrickx G . Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "Normal" coronary angiography. Circulation. 2001; 104(20):2401-6. DOI: 10.1161/hc4501.099316. View

13.

Kolozsvari R, Tar B, Lugosi P, Santa J, Beres Z, Ungvari T . Plaque volume derived from three-dimensional reconstruction of coronary angiography predicts the fractional flow reserve. Int J Cardiol. 2011; 160(2):140-4. DOI: 10.1016/j.ijcard.2011.04.010. View

14.

Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-81. PMC: 2988224. DOI: 10.1016/S0140-6736(10)61350-5. View

15.

Ben-Dor I, Torguson R, Gaglia Jr M, Gonzalez M, Maluenda G, Bui A . Correlation between fractional flow reserve and intravascular ultrasound lumen area in intermediate coronary artery stenosis. EuroIntervention. 2011; 7(2):225-33. DOI: 10.4244/EIJV7I2A37. View

16.

Park S, Kang S, Ahn J, Chang M, Yun S, Roh J . Effect of Statin Treatment on Modifying Plaque Composition: A Double-Blind, Randomized Study. J Am Coll Cardiol. 2016; 67(15):1772-1783. DOI: 10.1016/j.jacc.2016.02.014. View

17.

. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288(23):2998-3007. DOI: 10.1001/jama.288.23.2998. View

18.

Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K . Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015; 66(5):495-507. DOI: 10.1016/j.jacc.2015.05.065. View

19.

De Bruyne B, Fearon W, Pijls N, Barbato E, Tonino P, Piroth Z . Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014; 371(13):1208-17. DOI: 10.1056/NEJMoa1408758. View

20.

Kataoka Y, Hammadah M, Puri R, Duggal B, Uno K, Kapadia S . Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis. 2015; 242(2):490-5. DOI: 10.1016/j.atherosclerosis.2015.08.005. View